Latest news with #EricJoseph
Yahoo
19-05-2025
- Business
- Yahoo
JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News
On May 19, JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company's COVID-19 vaccine, however with limitations. A closeup of a vial of the biotechnology company's vaccines. The analyst noted that they view the approval as a solid near-term win for Novavax, Inc. (NASDAQ:NVAX), highlighting the expected milestone payment of $225 million from Sanofi. However, the vaccine has been approved with a label for only older and high-risk adults and requires a post-marketing commitment for an additional phase 4 efficacy study. Management believes the incremental costs related to this will be neutral for the operating expenses through 2027. Joseph justified his Underweight rating on Novavax, Inc. (NASDAQ:NVAX) as he anticipates the vaccine sales to be minimal in 2025, and the company is viewing the year as educational/observational. Moreover, the analyst noted that this indicates that the vaccine's market reputation will not be visible until the second half of 2026, thereby making the FDA approval only a near-term win. While we acknowledge the potential of NVAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVAX and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
15-05-2025
- Business
- Business Insider
J.P. Morgan Remains a Buy on Septerna, Inc. (SEPN)
J.P. Morgan analyst Eric Joseph maintained a Buy rating on Septerna, Inc. (SEPN – Research Report) yesterday. The company's shares closed yesterday at $10.16. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Joseph covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Bluebird Bio, and Rocket Pharmaceuticals. According to TipRanks, Joseph has an average return of 3.0% and a 46.12% success rate on recommended stocks. Currently, the analyst consensus on Septerna, Inc. is a Moderate Buy with an average price target of $19.00. Based on Septerna, Inc.'s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $212 thousand and a GAAP net loss of $20.67 million. In comparison, last year the company earned a revenue of $118 thousand and had a net profit of $34.89 million Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SEPN in relation to earlier this year. Most recently, in March 2025, Ezekowitz Alan, a Director at SEPN bought 13,319.00 shares for a total of $92,167.48.
